76 results about "Contrast-induced nephropathy" patented technology

A method of increasing renal function in a patient operates by stimulation of perivascular sympathetic nerves found in the vicinity of the hepatic portal vein and the hepatic artery. The method can be used as a treatment for renal failure or chronic kidney disease. Alternatively, the method can be used as a prophylactic treatment for preventing contrast-induced nephropathy or any other toxic nephropathy, which can result in renal failure. The perivascular sympathetic nerves can be stimulated by applying energy, such as electrical energy, light, vibration, and ultrasonic vibration, to the perivascular sympathetic nerves. Various methods are described for stimulating the perivascular sympathetic nerves using electrodes that are placed using minimally-invasive techniques.

The invention provides a stable nanoscale superparamagnetic iron oxide solution which is used as a contrast agent for magnetic resonance imaging (MRI). The superparamagnetic iron oxide solution is characterized in that the particle size of nanoscale superparamagnetic iron oxide particles is stabilized to between 60 and 75 nanometers when the superparamagnetic iron oxide solution is stored for 12 months at an environmental temperature of 4 to 38 DEG C, and the nanoscale superparamagnetic iron oxide particles are in high dispersibility and free from agglomerating or precipitating. After nanoscale superparamagnetic iron oxide solution containing 25mcg of iron, provided by the invention, is subjected to intravenous injection in the MRI of an early-stage in-situ hepatic cancer tumor live model of a rat, the imaging performance of the tumor in the MRI is obviously improved, the position, boundary and size of the tumor can be clearly displayed, and the tumor image effect remains significant after 24 hours; the phenomenon that the boundary and size of the tumor are unclear occurs in the MRI of the early-stage in-situ hepatic cancer tumor live model without contrast agent. Therefore, the nanoscale superparamagnetic iron oxide solution provided by the invention has a stable nanometer solution characteristic, is obvious in tumor impacting effect under low-dosage injection, and unique in innovation and application prospect.

The present invention disclose a specific positive magnetic nuclear resonance contrast agent and method of preparing the same, the contrast agent is applying gadopentetate dimeglumine (Gd-DTPA) coating or scion grafting to 1-100 nm hydroxylapatite [Ca [10](PO [4][6](OH)[2], short as HA) particles, to obtain composite granule smaller than 1000 nm, modified by proserum, polyethylene imine (PEI), polyethyleneglycol (PEG) to get dispersion stability colloid solution. Comparing with the present technology the positive magnetic nuclear resonance contrast agent of the invention is provided with low toxicity, high stability, good biocompatibility, high sensibility, high relaxation capability and liver, spleen specificity. The contrast agent colloid solution can be used for enhancing contrast imaging of human body or non-human body liver or spleen.

The present invention relates to methods of preventing contrast-induced nephropathy including the step of administering an effective amount of a compound (e.g., a peroxynitrite decomposition agent, a PARP inhibitor or a superoxide dismutase mimic) to a subject to be administered a contrast agent.

The present invention includes pharmaceutical composition comprising (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D₃-N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuventation, antimicrobial infection, Friedreich's ataxia.

The invention discloses a metal doped ferrite nano material and a preparation method of magnetic nano particles containing the same and application and products thereof. The metal doped ferrite is a metal doped iron oxides with the chemical general formula of MxFe3-xO4, wherein M represents metal elements selected from a VIIB group, a VIII group or a IIB group, X represents the concentration rangeof doping metal, and 0<x<=4. A Fe-Au nano composite material is applied to magnetic resonance imaging so that a high-quality MRI contrast medium with significantly excellent imaging performance, highmagnetic sensitivity and abundant MR T1 and T2 weight imaging signals, the distinguishing and inspecting of severe diseases of tumors, cardiovascular diseases, neural system diseases, skeleton musclediseases and the like can be improved, and therefore the error of medical imaging inspecting and the treatment cost are significantly reduced.

The invention relates to a method for detecting liver and kidney clearance rates of two diastereoisomers Gd-A and Gd-B of Primovist. The method is characterized in that during regular dose administration of Primovist ( for example, intravenous administration during magnetic resonance enhanced imaging), a low dose of iodinated contrast agent (about 1% of the conventional dose) is given at the sametime, a small amount of blood sample is extracted to obtain the plasma clearance rates of the iodinated contrast agent, the Gd-A and the Gd-B, the plasma clearance rate of the iodinated contrast agentis GFR, it is discovered in the method provided by the invention for the first time that the GFR can approximately replace the kidney clearance rates of the Gd-A and the Gd-B, and the liver clearancerates of the Gd-A and the Gd-B can be obtained by subtracting the GRF from the respective plasma clearance rates. By adopting the detection method provided by the invention, the liver and kidney clearance rates of the two isomers of Gd-A and Gd-B of the Primovist can be measured conveniently and accurately, a "gold standard" and individualized pharmacokinetic indicators are provided for the magnetic resonance liver function imaging of the Primovist, and the method plays guidance and reference roles for rational drug use and evaluation of liver and kidney functions.

The invention relates to the field of medical imaging, and in particular relates to a head and neck angiography method. The head and neck angiography method comprises the following steps of: (1), obtaining the basic data of an examined person including the sex, the age, the heart rate, the systolic pressure and the diastolic pressure; (2), substituting the obtained basic data of the examined person into a PT time calculation formula; (3), determining the scanning/exposure time T through a defined scanning range; (4), obtaining the total injection time according to the PT time and the exposuretime T, selecting the injection rate of a contrast agent to be 3.0-5.0 ml/s, and obtaining the total injection amount and the total amount of the contrast agent by calculation; and (5), setting the delay time to the PT time on a CT scanner, starting the exposure key of the CT scanner and a contrast agent injector at the same time, injecting the total amount of the contrast agent, then, continuously injecting the total amount of normal saline injection, and performing exposure by the CT scanner, so that an examination image is obtained. The head and neck angiography method in the invention is used for improving the imaging effect of blood vessels; the use amount of the contrast agent is used in a personalized manner; therefore, the radiation dosage is reduced; and the radiation injury of radiography on a patient and the rate of allergic reaction are reduced.

The invention belongs to the technical field of medical products and in particular relates to a porous pig tail catheter device and application therein in blood vessel and cavity radiography. The porous pig tail catheter device comprises a pig tail catheter, wherein at least one through hole group is arranged on the pig tail catheter; the pig tail catheter is internally provided with a hollow inner core tube matched with the pig tail catheter; the inner core tube extend into an end opening inside the pig tail catheter; the inner core tube is moved inside the pig tail catheter along the lengthdirection of the pig tail catheter; a contrast agent is introduced into the inner core tube; and the contrast agent is gushed out from an end part of the inner core tube and flows out from through holes in the pig tail catheter to implement radiography. The device has the advantage that radiography can be implemented in different positions once being fixed for one time.

The invention discloses a traditional Chinese medicine for preventing and treating contrast-induced nephropathy and a preparation method thereof. The traditional Chinese medicine is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 20 to 30 parts of rheum officinale, 20 to 30 parts of rabdosia rubescens, 20 to 30 parts of dandelion, 15 to 25 parts of japan clover herb, 15 to 25 parts of dicliptera chinensis, 15 to 25 parts of acanthopanax, 10 to 20 parts of purple flower holly leaf, 10 to 20 parts of fruit of princesplume ladysthumb, 5 to 15 parts of cypripedium macranthum, 5 to 15 parts of polyporus umbellatus, 5 to 15 parts of aconitum napellus, 2 to 8 parts of cassia twig, 2 to 8 parts of verbena, 2 to 8 parts of euphorbia pekinensis and 1 to 5 parts of moleplant seed. The traditional Chinese medicine for preventing and treating contrast-induced nephropathy disclosed by the invention takes common traditional Chinese medicinal raw materials as raw materials, is scientific in formula, low in cost and exact in treatment effect, does not have side effects, has the effects of clearing heat, detoxifying, inducing diuresis for removing edema, promoting blood circulation to remove blood stasis and invigorating the spleen for eliminating dampness, and can effectively prevent and treat contrast-induced nephropathy.

The invention discloses a preparation method and application of a capillary reconstruction (therapeutic angiogenesis) targeted magnetic resonance contrast agent, and belongs to the crisscross fields of nanometer material science and biomedical engineering. The capillary reconstruction (therapeutic angiogenesis) targeted magnetic resonance contrast agent is supermini super paramagnetism ferric oxide-polylactic acid-polyethylene glycol-maleimide-RGD cyclic pentapeptide (cRGDfC) nanoparticles, wherein the expression is cRGDfC-Maleimide-PEG-PLA-USPIO. The synthetical magnetic resonance contrast agent is a T2 weighting contrast medium, and the particle-size distribution is uniform. The contrast medium is high in targeting properties (specificity), high in stability, favorable in relaxation properties, and small in side effects in accordance with new vessels, and has favorable application prospects and potential using value for assessment of capillary stable reconstruction (therapeutic angiogenesis) of microvascular dysfunction related diseases.

The invention discloses a tumor diagnosis and treatment integrated nano material based on manganese base, a preparation method and application. According to the preparation method, albumin, hypericinand manganese chloride are added into an aqueous medium, and the product is self-assembled to form the tumor diagnosis and treatment integrated nano material. An efficient manganese-base nanoscale macromolecular contrast agent is prepared through self-assembly and has the advantages of being high in relaxation efficiency, long in in-vivo circulation time, rapid in kidney removal, high in targetingproperty and biocompatibility, small in toxic and side effect and the like. The nano material prepared by the invention has relatively high photodynamic conversion efficiency at 595nm, can be used asa photosensitizer to be applied to photodynamic therapy. In addition, the position and size of a tumor and the enrichment condition of the phototherapeutic agent in tumor tissue are monitored by means of a magnetic resonance technology, the nano material is used for evaluating the treatment effect, and magnetic resonance imaging-mediated photodynamic therapy diagnosis and treatment integration isachieved.

The invention discloses a device and method for obtaining outflow effect parameters based on perfusion images, and the method comprises the detection steps: continuously collecting the perfusion images and an artery input function after perfusion, aligning the perfusion images of a subsequent time phase with a first time phase image, and removing artifacts and images which cannot be aligned; the method comprises the following steps of: acquiring a perfusion image, converting the perfusion image into a contrast agent concentration image, acquiring a residual function of each pixel point in the perfusion image based on an Indicator-Dilution principle, and calculating an outflow effect parameter, and measuring the outflow effect of the tissue by fully utilizing a residual function curve in a quantitative post-processing process of the MR or CT perfusion image. The residual function curve reflects the response of the tissue to the pulse blood flow (containing the contrast agent), so that the descending part of the residual function is the direct response of the outflow effect of the contrast agent in perfusion, and the measured outflow effect parameter is more accurate than the direct use of the dynamic perfusion curve.

The invention relates to a method to prevent contrast-induced nephropathy during an imaging procedure. The method includes steps of positioning balloon catheters in a patient's renal arteries and renal veins and inflating the balloons of each catheter to block the flow of contrast media into the patient's kidneys.

The invention discloses a photoacoustic imaging contrast agent for cancer diagnosis as well as a preparation method and an application of the photoacoustic imaging contrast agent. The preparation method comprises the following steps: firstly, synthesizing a polydopamine-modified two-dimensional Ti3C2Tx nanosheet with the surface rich in -OH functional groups through a chemical oxidative polymerization method; coating the Ti3C2Tx nanosheet with hollow ZnSn(OH) 6 microspheres with positive electricity on the surfaces after amination modification through an electrostatic self-assembly effect, sothat a ZnSn (OH) 6/Ti3C2Tx heterostructure is formed; combining RGD to the amination modified Ti3C2TxMXene nanosheet wrapped by the hollow ZnSn (OH) 6 through the covalent bonding effect, and obtaining the hollow ZnSn (OH) 6-coated Ti3C2TxMXene nanosheet. Therefore, the contrast agent provided by the invention has excellent tumor targeting to a tumor site, has excellent real-time performance, sensitivity and accuracy during tumor imaging, and can be used for tumor diagnosis, imaging technology-oriented treatment and real-time monitoring. The contrast agent disclosed by the invention still hasan excellent imaging effect when the intravenous injection dosage of the contrast agent is as low as 13.1 [mu]g/mL.

The invention discloses CT equipment capable of measuring the weight and height of a patient. The CT equipment comprises a CT scanning bed and a CT rack. The CT scanning bed comprises a movable bed board, a front-back driving device, a lifting driving device and a weighing table. The movable bed plate is mounted on the front-back driving device in a front-back sliding manner; the front-back driving device is mounted on the lifting driving device in a lifting manner; the weighing platform is mounted at the bottom of the lifting driving device; the CT rack is provided with a main control device used for controlling the front-back driving device to move front and back, controlling the lifting driving device to move up and down and controlling the weighing table to start. The X-ray tomography device has a patient weight weighing function and a height measuring function, so that medical staff can comprehensively evaluate the dosage of a contrast agent during X-ray tomography and adjust and optimize the radiation dosage in a scanning scheme according to the weighed weight data and height data of the patient, and the X-ray tomography device is started to perform X-ray tomography on the diseased part of the patient; related operation is simple, convenient, fast, time-saving and labor-saving, and the device is particularly suitable for bedridden patients who are inconvenient to walk.

The invention discloses a method for establishing a rat contrast-induced nephropathy model. The method includes the following steps that 1, rats do not drink water within 24-55 hours; 2, iopromide isapplied to the rats who do not drink water within 24-55 hours to obtain the contrast-induced nephropathy model. After detecting renal damage markers such as serum creatinine after different water-forbidden time in the test, it comes to a conclusion through discussion that occurrence of CIN is promoted under suitable water-forbidden conditions, and there are no irreversible renal damage changes caused by water-forbidden operation factors. The operation steps in the modeling process are optimized, caudal vein furosemide injection operation is reduced, good vascular conditions are kept for injection of contrast agent, unnecessary intervention factors are reduced, the success rate of tail vein injection of the contrast agent and the success rate of model construction are increased, and the simplified and repeatable modeling process can be completed with fewer and effective steps.

The invention relates to the technical field of carrier drugs, in particular to a targeted drug nano system as well as a preparation method and application thereof. In order to solve the problems that an existing MRI contrast agent is large in toxicity, poor in specificity and low in accuracy and an existing drug is poor in targeting performance, the targeted drug nano system and the preparation method and application of the targeted drug nano system are provided, ferroferric oxide (Fe3O4) serves as a carrier, and by means of the superparamagnetism characteristic of DMSA@Fe3O4 magnetic nano particles, immunotherapeutic drugs and chemotherapeutic drugs are modified on the surfaces of the nanoparticles in a surface charge attraction mode. The targeted drug nano system can promote CD4 + cells to gather at a tumor site through combined treatment of immunization and chemotherapy, the curative effect is enhanced in a mutual promotion mode, in addition, real-time tracking of drugs and real-time monitoring of the curative effect can be achieved by means of MRI, and the effect of integration of diagnosis and treatment is achieved.

The invention discloses a nano-ultrasonic microbubble, as well as a preparation method and application thereof. The nano-ultrasonic microbubble has a shell-kernel structure, wherein the inner kernel is liquid fluorocarbon nano-particles and curcumin, and the shell is a lipid film; and the surface of the lipid film is coupled with CD44 antibody. The nano-ultrasonic microbubble has good imaging, canbe used as an ultrasonic developing contrast agent, a CT contrast agent and an MRI contrast medium, is a multifunctional contrast medium and shows specific superiority in the aspect of targeting development. The nano-ultrasonic microbubble can achieve transformation from nano-grade to micron-grade after accepting ultrasonic excitation, and can release coated drugs to improve the curative effect of sonodynamic treatment. Due to the common effects of nano-grade particle size, sound-sensitive agent curcumin and CD44 antibody, the nano-ultrasonic microbubble achieves excellent target property andtreatment effect in tumor treatment and can be used for treating ovarian cancer, cervical cancer, lung cancer, colorectal cancer, breast cancer and esophagus cancer.

The invention discloses a method for culturing a contrast agent damage model based on renal tubular epithelial cells. The method includes the steps of: (1) conducting HK-2 cell resuscitation; (2) performing cell subculture; (3) observing the culture period cell morphology under a microscope, when the cell edge crumples become round and the refractivity is enhanced, conducting centrifugation, and adding a complete medium to make a cell resuspension solution; (4) transferring the cell resuspension solution into a complete medium according to an inoculation density of 40%-50%; (5) when the cell growth density reaches 80%-90%, performing centrifugation, adding a complete medium to prepare a cell resuspension solution (with a cell concentration of 1.0-1.5*10<6>/ml); and (6) inoculating every 40-60microl of the prepared cell resuspension solution into a 2ml complete medium, conducting culture for 40-50h, then conducting replacing with a serum-free medium and performing culture for 4-8h, thenadding a 45-55mgI/ml iodixanol solution, and further conducting culture for 5-7h, thus obtaining damage model cells. The method provided by the invention can culture the cell damage model that has similar content to contrast-induced nephropathy patient postoperative serum HMGB-1 content, closer damage and fewer system toxins.

The present invention relates to compositions and methods for reducing the risk and/or extent of radiocontrast-induced nephropathy (“RIN”) for kidney-imaging procedures that employ a radiocontrast medium. It is based, at least in part, on the discovery that, in a renal tubular cell line, radiocontrast induced inflammatory upregulation and cell injury could be reduced by calcineurin inhibitors FK506 and cyclosporine.

The invention discloses a contrast-induced acute kidney injury detection system based on in-voxel incoherent motion MRI imaging. According to the system, the output end of a scanning module is connected with the input end of an imaging module; the output end of the imaging module is connected with the input end of a data input module; the output end of the data input module is connected with the input end of a central processing unit; the power output end of a power supply module is connected with the input end of the central processing unit; the output end of the central processing unit is connected with the input end of an image analysis module; and an IVIM model is adopted, so that the problem of large ADC value difference is well solved. For a kidney lesion, if the lesion is strengthened after a gadolinium agent is injected and no fat component is contained in the lesion, the lesion is generally a tumor which needs to be subjected to surgical excision; and IVIM and contrast-enhanced MRI researches are carried out on 31 focuses (15 enhanced ones and 16 non-enhanced ones) of 28 patients, and the accuracy during detection is improved.